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Abstract
Background and Aims
Chronic kidney disease (CKD) is a risk factor for development and progression of heart fail-
ure (HF). CKD and HF share common risk factors, but few data exist on the prevalence,
signs and symptoms as well as correlates of HF in populations with CKD of moderate sever-
ity. We therefore aimed to examine the prevalence and correlates of HF in the German
Chronic Kidney Disease (GCKD) study, a large observational prospective study.
Methods and Results
We analyzed data from 5,015 GCKD patients aged 18–74 years with an estimated glomeru-
lar filtration rate (eGFR) of<60 ml/min/1.73m² or with an eGFR60 and overt proteinuria
(>500 mg/d). We evaluated a definition of HF based on the Gothenburg score, a clinical HF
score used in epidemiological studies (Gothenburg HF), and self-reported HF. Factors as-
sociated with HF were identified using multivariable adjusted logistic regression. The preva-
lence of Gothenburg HF was 43% (ranging from 24% in those with eGFR>90 to 59% in
those with eGFR<30 ml/min/1.73m2). The corresponding estimate for self-reported HF was
18% (range 5%-24%). Lower eGFR was significantly and independently associated with
the Gothenburg definition of HF (p-trend<0.001). Additional significantly associated corre-
lates included older age, female gender, higher BMI, hypertension, diabetes mellitus, valvu-
lar heart disease, anemia, sleep apnea, and lower educational status.
Conclusions
The burden of self-reported and Gothenburg HF among patients with CKD is high. The pro-
portion of patients who meet the criteria for Gothenburg HF in a European cohort of patients
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with moderate CKD is more than twice as high as the prevalence of self-reported HF. How-
ever, because of the shared signs, symptoms and medications of HF and CKD, the Gothen-
burg score cannot be used to reliably define HF in CKD patients. Our results emphasize the
need for early screening for HF in patients with CKD.
Introduction
Chronic kidney disease (CKD) is a major public health problem affecting more than 10% of the
general population in many countries worldwide[1,2]. It is associated with high cardiovascular
disease (CVD) morbidity and mortality[3,4,5]. CVD is often underdiagnosed and undertreated
in patients with CKD[3]. Heart failure (HF) is one of the leading cardiovascular conditions in
patients with impaired renal function[6]. CKD and HF occur frequently together[6,7,8], and
epidemiological studies have found not only severely but already moderately reduced kidney
function to be an independent risk factor for both incident HF[9,10,11] and aggravation of prev-
alent HF[12]. HF prevalence is estimated as 1–2% in the industrial states overall, 6–10% in peo-
ple aged65[13,14], and 40–54% in persons aged65 who also have CKD[8].
In a recent report from the multi-ethnic Chronic Renal Insufficiency Cohort (CRIC), a US
population of mostly middle-aged patients with CKD, 11% of patients reported previously di-
agnosed HF and an additional 25% reported symptoms of HF[15]. Corresponding data from
patients with CKD of moderate severity are missing in Central Europe. The German Chronic
Kidney Disease (GCKD) study is one of the largest prospective observational studies of referred
CKD worldwide with 5217 Caucasian patients with CKD stage G3 or overt proteinuria enrolled
from 2010–12[16].
There are no gold standard criteria to define HF in epidemiological studies, especially when
the collection of echocardiogaphic data is not feasible. Many investigations use HF hospitaliza-
tions as a diagnosis criterion, which detects advanced disease but may miss patients with HF in
early stages, where detection followed by efficient therapy can still prevent its progression. In
this study, we aimed to investigate the prevalence, signs and symptoms as well as correlates of
HF at the baseline visit of the GCKD study. In order to assess whether patients with moderate
CKD already show signs and symptoms of HF found in its early stages, we evaluated the Goth-
enburg score, a validated clinical HF score that was developed to detect early HF [17,18,19].
We further evaluated a self-reported diagnosis of HF. The identification of HF, a frequent co-
morbidity in patients with CKD, or its clinical correlates represents an important first step to-
wards improved management.
Methods
Study Population and Design
The GCKD study was designed as a prospective observational study of patients with moderate
CKD in Germany to gain insights about the pathogenesis of CKD and its association with
CVD. Main study outcomes include CKD progression, incidence of end-stage renal disease,
cardiovascular events and mortality, and all-cause death. Details of the enrolment process and
study procedures are fully described elsewhere[16]. Briefly, 5217 CKD patients under routine
nephrological care were enrolled across nine German study centers. At the time of screening,
male and female patients aged 18 to 74 years had an estimated glomerular filtration rate
(eGFR) of 30–60 ml/min/1.73m2 (corresponding to the most prevalent CKD stage G3[20]), or
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overt proteinuria (albuminuria of>300 mg/g creatinine or proteinuria of>500 g/g creatinine)
in the presence of higher eGFR. Exclusion criteria were non-Caucasian ethnicity, active malig-
nancy, previous transplantations, HF stage NYHA IV, and legal attendance. All participants
gave written informed consent, and the German Chronic Kidney Disease study was approved
by the Ethics Committees of all participating institutions (Friedrich-Alexander-University
Erlangen-Nuremberg, Medical Faculty of the Rheinisch-Westfälische Technische Hochschule
Aachen, Charité—University Medicine Berlin, Medical Center—University of Freiburg, Medi-
zinische Hochschule Hannover, Medical Faculty of the University of Heidelberg, Friedrich-
Schiller-University Jena, Medical Faculty of the Ludwig-Maximilians-University Munich,
Medical Faculty of the University of Würzburg).
Data Collection
At the baseline visit, trained and certified personnel used standardized questionnaires to obtain
information about the patient´s medical history, socio-demographic and life-style factors,
medication intake and signs and symptoms of HF. The physical examination included mea-
surements of body weight and height, heart rate and three measurements of resting blood pres-
sure. Further information on the patients’medical history as well as additional medical records
were obtained from the patients’ treating nephrologists.
Assessment of Heart Failure
The Gothenburg score[17,18,19] is a validated HF screening tool for epidemiological studies
composed of three components: a cardiac score (positive if one or more of the following is pres-
ent: coronary heart disease (CHD), angina pectoris, edema, dyspnea at night, pulmonary rales
or atrial fibrillation), dyspnea on exertion, and the intake of HF medication. The presence of
manifest HF defined as Gothenburg stage 2 (presence of a positive cardiac score with either
dyspnea on exertion or HF medication) or stage 3 (presence of all three components) was eval-
uated. Pulmonary rales were not included since auscultation was not part of the physical exam.
Developed in 1987, the original Gothenburg score defined digitalis or loop diuretics as typical
HF medication. To allow for changes in treatment regimens over time, we included additional
HF medication and established a modified definition that was used for the analyses in this re-
port and was evaluated in several validation analyses (see below). HF according to the Gothen-
burg definition was compared to self-reported HF, which was assessed by asking the patients
“Are you suffering from heart failure/weakness of the heart?”.
Baseline Variables
All laboratory values were measured in a central certified laboratory using standardized proto-
cols as described in detail previously[21]. Kidney function and damage was assessed by eGFR
and the Urine Albumin-to-Creatinine Ratio (UACR) using the central laboratory measures
from the baseline visit. GFR was estimated using the CKD-EPI formula[22] and categorized
according to the KDIGO clinical practice guideline[23] into90 (G1), 60-<90 (stage G2),
45-<60 (stage G3a), 30-<45 (stage G3b) and<30 (stage G4/5) ml/min/1.73m2. These values
may differ from the screening values obtained from the treating nephrologists and resulted in
the inclusion of some patients with an eGFR<30 ml/min/1.73m2. Differences in creatinine val-
ues between screening and baseline can be explained by the time difference between the screen-
ing and the baseline visit, and/or by differences in the creatinine assay and/or procedures
between the central laboratory and the laboratories used by the treating nephrologists. UACR
was calculated as measured urinary albumin/urinary creatinine (mg/g) and categorized accord-
ing to the KDIGO classification[23] into<30, 30-<300 and300 mg/g. Systolic and diastolic
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blood pressure (SBP and DBP (mmHg)) were determined as the average of up to three mea-
sured values. Hypertension was defined according to the Guidelines of the European Society of
Hypertension and the European Society of Cardiology[24] as SBP140 mmHg or DBP90
mmHg or intake of antihypertensive medication. Diabetes mellitus was defined as HbA1c
6.5% or intake of antidiabetic medication according to the American Diabetes Society[25].
Anemia was defined as hemoglobin<12 g/dl (females) and<13 g/dl (males)[26]. Medication
intake, edema, CHD, sleep apnea, angina pectoris, dyspnea on exertion, dyspnea at night, cur-
rent smoking, alcohol consumption, chronic obstructive pulmonary disease (COPD), asthma
and educational level were obtained by standardized interviews. Atrial fibrillation (chronic or
intermittent) and valvular heart disease were obtained by interviewing the treating nephrolo-
gist. CHD was considered present when the participant had ever had a heart attack or under-
gone a coronary reperfusion procedure (bypass or angioplasty). Angina pectoris was classified
by the Rose questionnaire[27]. Medication intake was programmed using ATC-Codes[28]. Ed-
ucational level was categorized into9, 10 and>10 years according to the different German
school-types.
Validation Analyses
To examine the use of the Gothenburg score in a CKD population in more detail, several addi-
tional analyses were conducted. A subgroup analysis of the GCKD participants enrolled at the
Freiburg center (541 patients) was performed; plausibility checks were conducted in order to
ensure a representative sample. Additional medical records supplied by the treating nephrolo-
gists or from former hospitalizations were abstracted and used to identify 118 patients with
data on HF and/or echocardiographic examinations, 29 of whom had an echo-based and/or
clinically established HF diagnosis based on the medical abstraction (diagnosed acute or chron-
ic HF, cardiac decompensation, dilatative cardiomyopathy, or ICD-10 code for HF). Among
these 118 patients, sensitivity, specificity, positive predictive value (PPV) and negative predic-
tive value (NPV) were calculated comparing the prevalence of HF based on different defini-
tions (various Gothenburg score modifications and self-reported HF) to the prevalence of
abstracted HF. Gothenburg score modifications consisted of different combinations of current
guideline-based HF medication[29] including angiotensin-converting enzyme (ACE) inhibi-
tors, ARBs, β-blockers, mineralocorticoid receptor antagonists (MRA), loop diuretics, digitalis
and ivabradine. The combination of ACE inhibitors and either digitalis or loop diuretics or
ivabradine showed the best results in these analyses and was subsequently used to establish the
modified Gothenburg score used in this report.
Additional analyses were conducted evaluating patients that were recruited for low eGFR
separately from those recruited for high proteinuria, as well as analyses restricting the defini-
tion of manifest HF to Gothenburg stage 3.
Statistical Analyses
All analyses were conducted using STATA 12 (College Park, Texas). Analyses were limited to
5015 participants excluding those who were missing information needed to calculate eGFR or
UACR and to generate the Gothenburg score (see S1 Fig). Factors associated with prevalent HF
were selected for evaluation based on previously reported HF risk factors, listed as covariates
above. Descriptive statistics comparing risk factors between individuals with and without prev-
alent HF were generated using t-tests for continuous, chi-squared tests for categorical variables
and Wilcoxon rank-sum test for UACR. Adjusted risk factor associations for the presence of
Gothenburg HF and self-reported HF were obtained from multivariable adjusted logistic re-
gression models including pre-specified covariates of interest and study center. Variables that
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were part of the Gothenburg score, e.g. CHD and atrial fibrillation, were not included in the
multivariable model. Two-sided p-values of<0.05 were considered statistically significant.
Model fit was examined using goodness of fit tests. Associated covariates were compared for
the direction and magnitude of their association across the different definitions of HF. Effect
modifications of the association between eGFR and HF by UACR, sex, and diabetes were evalu-
ated by including the corresponding interaction terms into the regression models. To account
for potential confounders, stratified analyses were conducted by absence or presence of CHD,
asthma or COPD.
Results
Study population and baseline characteristics
Characteristics of the study population by eGFR categories are presented in Table 1; the major-
ity of patients had CKD stage G3a (33%) or stage G3b (36%). Consistent with the GCKD re-
cruitment strategy, the median UACR was high in individuals with early-stage CKD (stage
G1). The proportion of patients with CHD and diabetes mellitus was higher with more ad-
vanced CKD: from 4% (stage G1) to 29% (stage G4/5) for CHD and from 21% to 45% for
diabetes mellitus.
The characteristics of the GCKD study population by presence and absence of Gothenburg
or self-reported HF are compared in S1 Table. In these univariate analyses, eGFR and UACR
were lower and BMI was higher in patients with Gothenburg HF compared to those without
HF. Moreover, patients with Gothenburg HF were older, had more diabetes mellitus, CHD,
atrial fibrillation, valvular heart disease, anemia and sleep apnea, and had lower educational
attainment than patients without Gothenburg HF. Self-reported HF demonstrated similar
relationships.
Prevalence of heart failure
The prevalence of HF when applying the Gothenburg criteria was 43% (27% Gothenburg stage
2 and 16% Gothenburg stage 3), compared to 18% for self-reported HF. Of patients with self-
reported HF, 79% were also classified as having Gothenburg HF. The exact composition of the
Gothenburg score and the proportion of GCKD patients in each of its components are dis-
played in Table 2. Edema was the most common of the score components with 40%, followed
by CHD. S2 Table shows the components of the Gothenburg score separately for men and
women. A higher proportion of women reported edema and/or dyspnea on exertion, whereas
a higher proportion of men reported a history of coronary heart disease and/or the intake of
HF medication.
Fig 1 shows that the prevalence of both Gothenburg and self-reported HF was significantly
higher among individuals in lower eGFR categories (p-trend for both<0.001). The prevalence
of Gothenburg HF rose from 24% in CKD stage G1 to 59% in stage G4/5, whereas the preva-
lence of self-reported HF rose from 5% in CKD stage G1 to 24% in CKD stage G4/5.
Table 3 shows the prevalence of both HF definitions across different UACR categories and
separately among men and women as well as among individuals with and without diabetes
mellitus and CHD. HF according to the Gothenburg score showed the highest prevalence
(47%) among patients with normoalbuminuria (<30 mg/g) and similar prevalences (40 and
39%) among patients with micro- and macroalbuminuria (30-<300 and300 mg/g). The
prevalence of self-reported HF decreased with increasing UACR in these univariate analyses.
Gothenburg HF was more prevalent in female than in male patients (46% versus 41%), whereas
there was no appreciable sex difference in the prevalence of self-reported HF. Both HF defini-
tions showed a substantially higher prevalence in diabetic patients compared to non-diabetic
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patients (59% vs. 34% for Gothenburg HF and 26% vs. 13% for self-reported HF) and in pa-
tients with CHD compared to patients without CHD (79% vs. 34% for Gothenburg HF and
43% vs. 11% for self-reported HF).
Validation analyses
Twenty-five percent of the 118 patients with information on HF and/or echocardiographic ex-
aminations had a HF diagnosis. Compared to this information, the modified Gothenburg score
showed high sensitivity (83%) and a high negative predictive value (91%), moderate specificity
of 55% and a low positive predictive value of 38% (Table 4); the original Gothenburg score
showed similar results. Self-reported HF showed lower sensitivity (52%) and higher specificity
(89%). Additional sensitivity analyses evaluating patients that were recruited for low eGFR and
those recruited for high proteinuria led to similar results; the evaluation of other medication
Table 1. Characteristics of 5015 GCKD study participants by eGFR categories.
eGFR categories (ml/min/1.73 m2)
Characteristics 90 (n = 232; 4.6%)
CKD stage G1
60–89 (n = 860;
17.2%) CKD stage G2
45–59 (1663; 33.2%)
CKD stage G3a
30–44 (n = 1815; 36.2%)
CKD stage G3b
<30 (n = 445; 8.9%)
CKD stage G4/5
UACR (mg/g): median
(IQR)
531.3 (165.1, 1171.2) 43.5 (7.8, 441.0) 26.1 (6.8, 191.3) 57.6 (11.5, 352.5) 122.9 (23.2, 905.3)
UACR categories (mg/g)
< 30 12.1 (28) 45.0 (387) 52.0 (865) 40.8 (740) 29.0 (129)
30–299 22.0 (51) 25.7 (221) 27.7 (461) 32.1 (582) 32.4 (144)
300 66.0 (153) 29.3 (252) 20.3 (337) 27.2 (493) 38.7 (172)
Age (years) 41.9 (13.1) 55.7 (12.5) 61.4 (10.3) 62.6 (10.6) 63.5 (10.0)
BMI (kg/m2) 28.6 (6.7) 29.3 (5.9) 29.8 (5.8) 30.1 (6.0) 30.5 (6.2)
Male gender 52.2 (121) 54.4 (468) 61.9 (1030) 61.4 (1115) 62.9 (280)
Diabetes mellitus 21.1 (49) 27.8 (239) 35.1 (583) 38.1 (692) 44.9 (200)
Hypertension 91.8 (213) 90.5 (778) 94.7 (1574) 97.1 (1762) 98.4 (438)
Coronary heart disease 3.5 (8) 13.0 (112) 19.5 (325) 23.3 (422) 28.5 (127)
Atrial ﬁbrillation 2.6 (6) 6.1 (52) 8.2 (136) 11.5 (209) 13.1 (58)
Valvular heart disease 1.3 (3) 8.3 (71) 8.6 (142) 11.7 (211) 12.4 (55)
Sleep apnea 4.7 (11) 8.0 (69) 10.1 (168) 9.5 (173) 14.2 (63)
Anemia 12.7 (28) 14.6 (122) 18.1 (292) 28.9 (511) 45.9 (196)
Hemoglobin (g/dl) 14.04 (1.99) 13.91 (1.83) 13.81 (1.65) 13.38 (1.78) 12.76 (1.61)
Serum Albumin (g/l) 36.2 (5.9) 38.2 (4.8) 38.8 (4.0) 38.4 (4.0) 37.5 (4.1)
Heart rate (bpm) 74.3 (10.3) 71.1 (12.5) 70.2 (11.8) 69.9 (12.3) 70.5 (12.5)
Current smoker 34.9 (81) 18.6 (159) 14.0 (232) 14.7 (266) 14.4 (64)
Alcohol intake ( 3
times per week)
14.7 (34) 20.4 (174) 21.2 (352) 17.1 (308) 17.9 (79)
Education
9 years 32.6 (73) 46.3 (388) 52.6 (857) 60.5 (1080) 64.0 (281)
10 years 32.6 (73) 32.6 (273) 31.1 (506) 24.9 (445) 23.7 (104)
>10 years 34.8 (78) 21.1 (177) 16.3 (265) 14.6 (260) 12.3 (54)
Data are mean (SD) for continuous variables and percentages (count) for categorical variables. Missing values in following variables (number of
missings): BMI (57), atrial ﬁbrillation (12), valvular heart disease (42), anemia & hemoglobin (145), serum albumin (1), heart rate (49), current smoker (12),
alcohol intake (28), education (101).
Valvular heart disease: aortic stenosis (n = 73), aortic insufﬁciency (n = 142), mitral stenosis (n = 15), mitral insufﬁciency (n = 251), other (n = 169). Some
individuals had more than one type of valvular heart disease.
doi:10.1371/journal.pone.0122552.t001
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combinations including ß-blockers and MRAs and only counting Gothenburg stage 3 as mani-
fest HF did not show higher measures of validity.
Factors associated with heart failure
Table 5 presents factors associated with one or both HF definitions obtained from a multivari-
ate adjusted logistic regression model. Many risk factor associations were statistically signifi-
cant and of similar magnitude across the two HF definitions, but some factors showed
differences. Gothenburg HF was significantly associated with lower eGFR: compared with indi-
viduals in CKD stage G3a, the odds ratio of Gothenburg HF among individuals with stage G3b
CKD was 1.18 (95% CI 1.01–1.39), and 1.71 among those with stage G4/5 CKD (95% CI 1.32–
2.20). In comparison with individuals with normoalbuminuria, microalbuminuria was inverse-
ly associated with prevalent Gothenburg HF (OR 0.81, 95% CI 0.69–0.95), whereas the associa-
tion of macroalbuminuria was not significant. In contrast, prevalent self-reported HF was not
significantly associated with eGFR-categories although the odds ratios also increased with
lower eGFR, and was inversely associated with macroalbuminuria but not microalbuminuria.
Adjustment for ACE inhibitor or ARB intake did not change the association between albumin-
uria and Gothenburg or self-reported HF. Male gender was inversely associated with Gothen-
burg HF (OR 0.65, 95% CI 0.57–0.76), whereas there was no significant association with self-
reported HF. There were no significant interactions between category of eGFR and UACR,
diabetes or sex for either definition of HF (all p>0.3).
To evaluate if the strong associations with Gothenburg HF would persist when excluding
patients with self-reported HF, we conducted a multivariate logistic regression for the 3,789 pa-
tients without self-reported HF and with full covariate information (S3 Table). The association
of both stage G3b and stage G4/5 CKD with Gothenburg HF remained essentially unchanged
(OR 1.18 and 1.85, respectively) although significance was attenuated due to smaller sample
size. All other associations remained significantly associated with similar odds ratios.
We conducted a number of further analyses to assess whether additional confounders were
likely to be important. To explore if the GCKD recruitment strategy (inclusion for low eGFR
vs. high proteinuria) had an influence on the associations of UACR with HF, we performed the
multivariate analysis only for patients that had been recruited based on eGFR<60 ml/min/
1.73m2 and had full covariate information (n = 4,278) and observed very similar results (S4
Table). Secondly, asthma and COPD as potential alternative causes for dyspnea on exertion
Table 2. Composition of the Gothenburg score and proportions of GCKD participants within the cardiac score components.
Gothenburg stage Symptoms and ﬁndings GCKD cohort
0: No HF No history, no signs, no HF medication 42%
1: Latent HF Cardiac score  1 15%
2: Manifest HF Cardiac score  1 and dyspnea on exertion or 17%
Cardiac score  1 and HF medication 10%
3: Manifest HF Cardiac score  1, dyspnea on exertion and HF medication 16%
Cardiac score Points  1 58%
Coronary heart disease 1 20%
Angina pectoris 1 9%
Edema 1 40%
Dyspnea at night 1 13%
Atrial ﬁbrillation 1 9%
Pulmonary rales 1 Not obtained in GCKD
doi:10.1371/journal.pone.0122552.t002
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Fig 1. Prevalence of heart failure across eGFR categories. The prevalence of both self-reported and
Gothenburg score heart failure is higher with lower eGFR category, with Gothenburg heart failure observed at
least twice as much in each category compared to self-report. P-trend was determined from logistic
regressions of each heart failure definition on categorized eGFR.
doi:10.1371/journal.pone.0122552.g001
Table 3. Prevalence of heart failure in UACR categories, by gender, presence of diabetes mellitus and
CHD.
Gothenburg score self-report
Overall (n = 5015) 42.8 (2146) 17.7 (889)
UACR categories (mg/g)
<30 (n = 2149) 46.9 (1008) 21.3 (457)
30–299 (n = 1459) 40.0 (584) 17.6 (257)
300 (n = 1407) 39.4 (554) 12.4 (175)
p-value <0.001 <0.001
Female (n = 2001) 45.6 (913) 16.9 (338)
Male (n = 3014) 40.9 (1233) 18.3 (551)
p-value 0.001 0.207
Non-diabetic (n = 3252) 34.3 (1115) 13.2 (429)
Diabetic (n = 1763) 58.5 (1031) 26.1 (460)
p-value <0.001 <0.001
No CHD (n = 4021) 34.0 (1365) 11.4 (459)
CHD (n = 994) 78.6 (781) 43.3 (430)
p-value <0.001 <0.001
Data are percentages (count). P-values are provided for a comparison of characteristics within a given
deﬁnition of HF, e.g. proportion of men and women with self-reported HF.
doi:10.1371/journal.pone.0122552.t003
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Table 4. Validation analyses within a subsample of the regional center Freiburg (n = 118).
Sensitivity Speciﬁcity PPV NPV
Gothenburg (modiﬁed deﬁnition) 83 55 38 91
Gothenburg (original deﬁnition) 83 54 38 91
Self-reported heart failure 52 89 60 85
Data are percentages.
Reference is heart failure diagnosis based on abstraction of medical records of the treating nephrologists or former hospitalizations. Sensitivity is the
proportion of patients with heart failure according to the respective evaluated deﬁnition out of the patients with heart failure according to the reference
deﬁnition. Speciﬁcity is the proportion of patients without heart failure according to the respective deﬁnition out of the patients without heart failure
according to the reference deﬁnition. Positive predictive value (PPV) is the proportion of patients with heart failure according to the reference deﬁnition out
of the patients with heart failure according to the evaluated deﬁnition. Negative predictive value (NPV) is the proportion of patients without heart failure
according to the reference deﬁnition out of the patients without heart failure according to the evaluated deﬁnition.
doi:10.1371/journal.pone.0122552.t004
Table 5. Multivariable adjusted analyses of factors associated with Gothenburg HF and self-reported HF (n = 4,604).
Gothenburg HF Self-reported HF
OR 95% CI P OR 95% CI P
eGFR (ml/min/1.73 m2)
90 0.87 0.59–1.29 0.049 0.56 0.27–1.14 0.111
60–89 1.07 0.88–1.31 0.485 1.16 0.90–1.49 0.264
45–59 (reference) ref ref ref ref ref ref
30–44 1.18 1.01–1.39 0.036 1.12 0.92–1.36 0.253
<30 1.71 1.32–2.20 <0.001 1.29 0.96–1.74 0.088
UACR (mg/g) (reference: <30) ref ref ref ref ref ref
30–299 0.81 0.69–0.95 0.010 0.87 0.71–1.05 0.147
300 0.87 0.72–1.04 0.126 0.70 0.55–0.88 0.002
Age (5 year intervals) 1.13 1.09–1.17 <0.001 1.15 1.10–1.22 <0.001
Male gender 0.65 0.57–0.76 <0.001 1.01 0.84–1.21 0.930
Diabetes mellitus 1.64 1.42–1.90 <0.001 1.61 1.35–1.92 <0.001
Hypertension 1.81 1.27–2.59 0.001 1.90 1.11–3.26 0.020
Valvular heart disease 2.52 2.01–3.15 <0.001 3.98 3.19–4.97 <0.001
BMI (kg/m2) 1.10 1.09–1.11 <0.001 1.04 1.03–1.06 <0.001
Sleep apnea 2.22 1.76–2.81 <0.001 2.15 1.70–2.73 <0.001
Anemia 1.39 1.18–1.63 <0.001 1.06 0.88–1.29 0.534
Education (reference: 9 years) ref ref ref ref ref ref
10 years 0.84 0.72–0.99 0.037 0.94 0.77–1.15 0.534
>10 years 0.69 0.56–0.84 <0.001 1.00 0.78–1.29 0.977
Serum albumin (g/l) 0.95 0.94–0.97 <0.001 0.99 0.98–1.02 0.993
Heart rate (bmp) 0.99 0.99–1.00 0.584 0.99 0.98–0.99 0.011
Current smoker 0.97 0.80–1.17 0.752 0.98 0.76–1.26 0.864
Alcohol intake ( 3 times per week) 0.98 0.82–1.17 0.827 0.97 0.79–1.21 0.802
Of 5,015 observations, values were missing values in BMI (57), valvular heart disease (42), anemia (145), serum albumin (1), education (101), heart rate
(49), current smoker (12), alcohol intake (28).
doi:10.1371/journal.pone.0122552.t005
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were included into the multivariate model with similar results. In addition, stratifying the pa-
tients for the presence or absence of asthma and of COPD also did not alter the associations
observed above. Lastly, the inclusion of CHD into the multivariate model showed a highly sig-
nificant association with both Gothenburg (OR 6.30, 95% CI 5.19–7.64) and self-reported HF
(OR 4.42, 95% CI 3.67–5.33) and led to a slight attenuation of some of the other associations,
but all remained highly significant. However, since CHD is one of the variables on which the
Gothenburg score is based, it was not included in the primary model testing risk factor associa-
tions with prevalent HF.
Discussion
In this cross-sectional analysis of a German CKD population, 43% met the criteria of the Goth-
enburg HF score, and 18% self-reported the presence of HF. The prevalence of HF from both
definitions was significantly higher among individuals with lower eGFR. These observations
show that a large fraction of patients with moderately severe CKD shows signs and symptoms
of HF although many of the patients are not aware of a HF diagnosis.
Only few studies have conducted cross-sectional epidemiological investigations that address
the prevalence, signs and symptoms and correlates of HF in patients with CKD, and our study
is the first to explore these questions in a large European CKD cohort. A recent investigation in
the CRIC Study showed that in a US population of patients with CKD, 11% reported previously
diagnosed HF and an additional 25% reported symptoms of HF. The authors concluded that
those symptoms likely indicate the presence of early HF in many of the participants[15]. The
HF symptoms evaluated in the CRIC Study included dyspnea and edema, which were also part
of the Gothenburg score used in our analyses. The proportion of patients with HF as defined
by the Gothenburg score was even higher in GCKD, which might be due to the fact that the
Gothenburg score incorporates also medication intake as well as due to the exclusion of ad-
vanced HF stages (NYHA III and IV) in CRIC, whereas only individuals with HF NYHA IV
were excluded from GCKD. Another investigation of an older population (Medicare patients
65 years) with non-dialysis-dependent CKD showed a prevalence of advanced HF identified
through hospitalization codes of 40% among non-diabetic and 54% among diabetic patients
[8]. In an analysis of the population-based NHANES survey, prevalent self-reported HF rose
from 7% in patients with CKD G3b to 28% in stage G4[30]. The high prevalence of HF or of
its signs and symptoms observed in our study is thus supported by similar estimates from
other studies.
We observed a strong association between lower eGFR and HF, which remained significant
for Gothenburg HF after multivariate adjustment. This is consistent with other studies that
have shown an independent association between lower eGFR and HF[9,11] as well as general
CVDmorbidity and mortality risk[5]. Contrary to some reports[5] that have shown increased
albuminuria to be associated with CVD, our multivariable adjusted analyses did not identify a
significant association between increased albuminuria and HF, but in fact an inverse associa-
tion between albuminuria and HF. To explore whether this observation might be related to the
recruitment strategy in the GCKD study, we conducted multivariable adjusted analyses re-
stricted to 4,278 individuals recruited based on eGFR<60 ml/min/1.73m2 and full covariate
information (S4 Table). The inverse association between increased albuminuria and HF per-
sisted, which suggests that the GCKD recruitment scheme is not sufficient to explain the ab-
sence of the previously reported association of higher UACR with HF. A potential explanation
that may contribute to differences observed to previous population-based samples is the high
intake of medications that impact the UACR in a CKD population.
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Risk factor associations with HF were evaluated with a focus on previously reported factors
and comorbidities[14]. Older age, higher BMI, the presence of hypertension, diabetes mellitus,
valvular heart disease, sleep apnea, and anemia as well as lower educational attainment were
significantly associated with prevalent HF. Generally, males have been reported to be at higher
risk to develop HF, especially HF with reduced ejection fraction and of ischemic etiology[31].
Our analyses revealed no association between male sex and self-reported HF, but a significant
inverse association between male sex and the Gothenburg definition of HF. A potential expla-
nation for this observation could be a high proportion of patients with HF with preserved ejec-
tion fraction (HF-PEF) in the GCKD Study, which is more common in females and patients
with hypertension[14,31,32]. This hypothesis is supported by the observation that left ventricu-
lar diastolic dysfunction is frequent among patients with CKD[33]. In addition, awareness may
be lower in patients with HF-PEF than in patients with HF with reduced ejection fraction,
which is associated with male sex and ischemic etiology[14,31]. Together, these observations
could explain that—in contrast to self-reported HF—the Gothenburg score is associated with
female sex in our study. Another explanation of the higher prevalence of Gothenburg HF in
women may be the higher proportion of women reporting edema, which other than from HF
or CKD could also result from venous circulation disorders that are more commonly observed
in women.[34] The stronger association between lower eGFR and Gothenburg HF compared
to self-reported HF could be influenced by a more sensitive definition of Gothenburg HF, or by
the lower specificity leading to the inclusion of more patients into the Gothenburg definition
where signs and symptoms of HF were in fact due to CKD rather than HF.
The association between HF and CKD is bi-directional. A recent investigation of the ESC
Heart Failure Pilot survey has demonstrated that in a cohort of patients with chronic HF, CKD
was prevalent in 41% and was independently associated with a higher risk of mortality and HF
hospitalization[35]. The contribution of heart diseases to worsening renal function and vice
versa have been described as cardio-renal-syndromes[36]. The association between CKD and
HF/CVD can only partly be explained by common risk factors and comorbidities like older
age, hypertension, diabetes mellitus and atherosclerosis; independent associations between a
decline in renal function and CVD/HF have been found[3,4,5].
The Gothenburg score is a HF screening tool that was developed to detect HF already in its
early stages in epidemiological studies and to differentiate between cardiac and pulmonary
causes of dyspnea[17,18,19]. A study in a community-based population reported a sensitivity of
84% and specificity of 81%, compared to the gold standard definition of HF based on the Guide-
lines of the European Society of Cardiology[37]. Our study is the first to investigate the use of
the Gothenburg score in a cohort of CKD patients. In our subgroup analysis, most of the indi-
viduals with a HF diagnosis based on echocardiography were captured by the Gothenburg HF
definition (sensitivity of 83%). The negative predictive value of 91% supports that individuals
who do not meet the Gothenburg score definition of HF do in fact not suffer from diagnosed
HF, which will be useful to determine the incidence of HF in future longitudinal analyses of the
GCKD cohort where patients with prevalent HF have to be excluded. The moderate specificity
of 55% and the low positive predictive value of 38% indicate that Gothenburg HF definition
contains false positives but its high NPV indicates its potential usefulness as a screening test to
identify patients to undergo echocardiographic examinations. It needs however be taken into ac-
count that the echocardiographical examinations had been performed upon some indication
rather than among everyone, such that early forms of HF and HF with preserved ejection frac-
tion might have been underdiagnosed.
A likely alternative explanation for the false positive assignment of HF based on the Gothen-
burg score might be that the symptoms and signs used for the composition of the Gothenburg
score cannot uniquely be attributed to HF but could also result from other diseases, e.g. dyspnea
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from pulmonary diseases or because of obesity. Adjustment for these potential confounders—
obesity, asthma and COPD—did however not alter the observed results. Moreover, edema,
which is also part of the Gothenburg score, is a typical sign of both HF and CKD and was pres-
ent in 40% of the GCKD cohort. Furthermore the medication that is part of the Gothenburg
score definition is not specific for HF but could also have been prescribed for other reasons, e.g.
ACE inhibitors for hypertension or proteinuria, but it is not possible to obtain information
about the indication of prescriptions in epidemiological studies. Taken together, the Gothen-
burg score cannot be used to reliably define HF in CKD patients, because both diseases share
signs, symptoms and medications. Nevertheless, the high prevalence of HF signs and symptoms
in CKD patients warrants a cardiologic evaluation of these patients for the presence of HF.
Our results have several clinical implications. Because both CKD and HF can lead to hyper-
volemia, it is difficult for physicians to detect HF in patients with CKD. However, assessing the
presence of HF and improving awareness of the condition as a frequent comorbidity in patients
with CKD represents an important first step towards early initiation of therapeutic manage-
ment. This should include consequent HF monitoring and treatment as well as attention to
and treatment of common risk factors like hypertension, diabetes mellitus, obesity and anemia
that can contribute to the worsening of both HF and CKD. Because some medications such as
ACE inhibitors are prescribed both for HF and for CKD, patients using ACE inhibitors may
have a therapeutic benefit even if HF is not diagnosed. Both CKD and HF are global public
health problems increasing with older age. Consequently the prevalence of both diseases sepa-
rately or concomitantly and their associated costs will rise even more in the future in aging
industrial populations.
Several limitations warrant mention: first, it was not feasible to conduct echocardiographic
examinations as part of the GCKD visits, since the exams took place at many different sites pre-
cluding the use of comparable devices and protocols. However, data from echocardiographic
examinations conducted outside the study visits that were available in the medical records of a
sub-cohort were used for validation analyses. The Gothenburg score is based on medications
and signs and symptoms of disease that may result both from HF and CKD as well as their
combination, such that in a CKD population, the score can be used to quantify the presence of
these signs and symptoms but not to diagnose HF. Moreover, sufficient information to be able
to differentiate between acute decompensated HF and chronic stable HF was not available.
This shortcoming of the Gothenburg score has been observed by others in epidemiological set-
tings[38]. Second, the available data are cross-sectional and thus do not allow to infer temporal
relationships. Third, residual confounding of associations through unknown risk factors may
remain. Fourth, we examined a homogeneous cohort of German CKD patients under nephro-
logical care, so they may not be generalizable to CKD in other settings or more advanced stages
of the disease. Notable strengths of our study include its large sample size, which ensures high
statistical power, the use of standardized questionnaires and in-person study visits conducted
by trained study nurses, which reduces heterogeneity, the collection of detailed medication in-
formation, and reliable estimation of kidney function based on central measurements of all
laboratory values.
In summary, use of the Gothenburg score to assess HF in a European cohort of patients
with moderately severe CKD leads to prevalence estimates that are more than twice as high as
those for self-reported HF. Lower eGFR was a significant independent correlate of Gothenburg
HF. Because of the shared signs, symptoms and medications of HF and CKD, the Gothenburg
score is not useful to reliably define HF in the setting of CKD, but our results emphasize the
need to evaluate CKD patients with HF signs and symptoms for the presence of HF as a first
step for its early identification and treatment.
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